Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    A 3D Printed Drug?

    Several readers have sent along news of what’s billed as the “world’s first 3D-printed drug”. That got my attention, because there have been some rather wild predictions about the effects of that technology on drug discovery, some of them weird in the extreme. On checking this out, though, I found that it would be more accu… Read More
  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
  • Drug Development

    The Sunk Cost Fallacy

    Mentioning target validation yesterday led me to think about an even larger problem: the sunk cost fallacy. That’s a general human tendency, but (like several other human tendencies) it can lead to some wasted scientific effort. A “sunk cost”, in economic terms, is an unrecoverable one – it’s gone, it’s spent, an… Read More
  • Drug Assays

    Target (In)validation

    Here’s a short review in ACS Medicinal Chemistry Letters on target validation. As the author (Ramzi Sweis of AbbVie) says, it’s easy for medicinal chemists to lose track of that being part of their role: Too often, medicinal chemistry teams blindly accept the biological underpinnings of a new program as sound and are unaware that… Read More
  • Business and Markets

    Two Types of Risk

    It’s the time for the ASCO meeting again, so everyone who follows oncology drug development will be busy catching up on the news. Bruce Booth has a good overview of things here, based on look at the abstracts submitted for the meeting. An analysis of the words mentioned in them shows some interesting features: the… Read More
  • Drug Development

    Hubris Watch

    I like scientific progress a lot. And we’ve had quite a bit of it in recent years in immunotherapy and gene editing; no one can doubt it. But there still seems to be something a bit off with the quotes below. These are the CEOs of Bluebird and Agios, speaking at the National Venture Capital… Read More
  • Drug Development

    What Are the Odds of Finding a Drug (And How Do You Stand Them?)

    Lisa Jarvis of C&E News asked a question on Twitter that’s worth some back-of-the-envelope calculation: what are the odds of a medicinal chemist discovering a drug during his or her career? And (I checked) she means “personally synthesizing the compound that makes it to market”. My own hand-waving guesstimate of an upper boun… Read More
  • Drug Development

    Best And Worst Areas for Drug Discovery

    I’m traveling today, with no time to do a full blog post. So I’m going to toss out a couple of questions for everyone: What diseases or therapeutic areas do you think have the best opportunities now for “traditional” small-molecule drug discovery? And which ones do you think have the worst or fewest? All factors… Read More
  • Business and Markets

    China’s First Homegrown Pharma

    The Wall Street Journal had an article on a new HDAC inhibitor from Shenzhen Chipscreen (full text here from The Australian). It’s worth highlighting. Epidaza (chidamide) appears to be the first homegrown drug discovery and development effort to reach regulatory approval in China. Their founder, Xian-Ping Lu, was working at Galderma before he… Read More
  • Clinical Trials

    Levels of Data

    Here’s a brief article in Science that a lot of us should keep a copy of. Plenty of journalists and investors should do the same. It’s a summary of what sort of questions get asked of data sets, and the differences between them. There are six broad data analysis categories: 1. Descriptive. This is the… Read More